PARProceedings of Anticancer Research2208-35452208-3553Bio-Byword Scientific Publishing Pty. Ltd.10.26689/par.v10i2.14548ArticleResearch Progress and Clinical Translation of Combined Targeted Therapy and Immunotherapy for Liver Cancerhttps://artdesignp.com/journal/PAR/10/2/10.26689/par.v10i2.14548YuGuodong,TianXixi20261022026-04-14Primary liver cancer is a highly prevalent malignant tumor worldwide, with hepatocellular carcinoma (HCC) being characterized by insidious onset and rapid progression. Most patients are diagnosed at advanced stages, losing the opportunity for radical surgery, making systemic therapy the core approach to prolong survival and improve quality of life. Historically, molecular targeted therapy has been the mainstay of systemic treatment for advanced liver cancer, offering some control over tumor progression but with limitations such as low objective response rates, frequent drug resistance, and limited survival benefits. The advent of immune checkpoint inhibitors has revolutionized the landscape of systemic liver cancer therapy, providing hope for long-term survival in advanced patients through their unique mechanism of reshaping the tumor immune microenvironment and activating endogenous anti-tumor immunity. However, monotherapy with immune checkpoint inhibitors is effective only in a minority of immunologically favorable patients, limiting overall benefit. In recent years, the combination of targeted therapy and immunotherapy (targeted-immunotherapy combination) has broken through the efficacy bottleneck of monotherapy through synergistic anti-tumor effects, becoming the standard first-line treatment for advanced liver cancer. This article provides a comprehensive review of the mechanisms of action, core clinical research progress, and optimization strategies for clinical translation of targeted-immunotherapy combination therapy in liver cancer, aiming to provide references for clinical practice and future research in this field.

Lu S, Yu H, Luo P, et al., 2022, Analysis of Changes in the Burden of Liver Cancer in Jiangsu Province from 1990 to 2019. China Cancer, 31(6): 450–456.

Zeng K, Wang X, Mao X, 2026, Progress in Clinical Research on Drug Therapy for Hepatocellular Carcinoma. Oncology Pharmacy, 1: 1–9.

Fu J, Xu C, Miao D, et al., 2024, Research Progress on Signaling Pathways Related to Liver Cancer Development and Their Molecular Targeted Drugs. Shandong Medical Journal, 64(25): 95–98.

Hiroko I, Ghmkin H, et al., 2021, Cripto-1 as a Potential Target of Cancer Stem Cells for Immunotherapy. Cancers, 13(10): 2491.

Wen L, Gan X, Cao Y, et al., 2026, The Role of Ferroptosis in the Development, Progression, and Treatment of Liver Cancer: Mechanisms, Targeted Strategies, and Translational Prospects. Chinese Journal of General Surgery, 35(1): 169–179.

Huang Y, Lan X, Zhu M, et al., 2024, Research Progress on PD-1/PD-L1 Inhibitors Combined with Anti-Vascular Endothelial Growth Factor Drugs for Immunotherapy of Advanced Liver Cancer. Chinese Pharmacological Bulletin, 40(8): 1429–1436.

Liu Y, Tang X, Cheng M, 2026, Progress in Non-Invasive Detection Methods for Acute Rejection after Liver Transplantation. Organ Transplantation, 17(2): 296–303.

Han Z, Wang H, Zhao J, 2025, Research Progress on the Role of GLUL in Drug Resistance Mechanisms of Hepatocellular Carcinoma. Life Sciences, 37(10): 1360–1371.

Zhang P, Xing W, Xie P, et al., 2026, Research Progress in Immunotherapy for Hepatocellular Carcinoma. Chinese Advances in General Surgery, 29(2): 127–133.

Zheng Y, Duan S, Zhou P, 2026, Research Progress on the Functional Regulatory Mechanisms and Therapeutic Potential of CD8+ T Cells in Pulmonary Antiviral Infection and Anti-Tumor Immunity. Chinese Journal of Cell Biology, 48(3): 581–594.

He L, Liu X, 2026, Current Status and Considerations of Combination Therapy in Immunotherapy for Hepatocellular Carcinoma. Chinese Journal of Immunology, 42(3): 742–748.

Zheng Y, Wang H, 2026, Functional Subtypes of Macrophages in the Tumor Microenvironment from a Single-Cell Perspective. Chinese Journal of Cell Biology, 48(2): 465–477.

Bi J, Chang Q, Wang C, 2025, Observation of the Efficacy of Pembrolizumab Combined with Bevacizumab in the Treatment of Advanced Metastatic Liver Cancer. Pharmaceutical Biotechnology, 32(6): 804–808.

Su Z, Che J, Pei R, 2024, Real-World Study of Sintilimab Combined with Bevacizumab in Advanced Hepatocellular Carcinoma. Chinese Pharmacist, 27(3): 485–490.

Chen F, 2026, Clinical Efficacy of Tislelizumab Combined with Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma. Clinical Rational Drug Use, 2026, 19(5): 18–21.

Feng S, Zhou J, Wei X, et al., 2025, Research Progress on Clinical Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Cancer Progress, 23(19): 2238–2243 + 2262.

Xu W, Feng Y, He P, et al., 2026, Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitors in Patients with Advanced Hepatocellular Carcinoma. Journal of Shandong First Medical University (Shandong Academy of Medical Sciences), 47(1): 21–30.

Qin S, Fan J, Yang F, et al., 2024, LBA38 Iparomlimab and Tuvonralimab (QL1706) with Bevacizumab and/or Chemotherapy in First-Line (1L) Treatment of Advanced Hepatocellular Carcinoma (aHCC): A Randomized, Open-Label, Phase II/III Study (DUBHE-H-308). Ann Oncol, 35: S1229–S1230.

Su Y, Liang Y, Huang X, 2026, Latest Research Status of Targeted and Immunotherapy for Advanced Hepatocellular Carcinoma. Chinese Journal of Bases and Clinics in General Surgery, 1: 1–11.

Liu Y, Gao Q, 2024, Integration of Targeted Immunotherapy and Surgical Treatment for Primary Liver Cancer. Journal of Hepatobiliary Surgery, 32(1): 67–70.

Cao J, Zhang Z, 2026, Logical Thinking in Surgical Decision-Making for Controversial Resectable Liver Cancer. Abdominal Surgery, 39(1): 35–40.

Jiang S, Ding D, Zu Y, et al., 2025, Current Status and Progress in Clinical Treatment of Intermediate-Stage Primary Liver Cancer. Chinese Journal of Practical Surgery, 45(12): 1461–1470.

Zheng K, Wang X, 2025, TACE Combined with HAIC for Advanced Hepatocellular Carcinoma: Technical Concepts and Clinical Practice. Chinese Journal of Bases and Clinics in General Surgery, 32(12): 1505–1510.

Special Committee on Whole-Course Management of Liver Diseases, Chengdu Society of Biomedical Information, 2026, Expert Consensus on the Whole-Course Management of Hepatitis B Virus-Related Hepatocellular Carcinoma: The Role and Practical Path of the Infectious Diseases Department (2026 Edition). Journal of Clinical Internal Medicine, 43(1): 78–85.

Zhou X, Qin D, Li Z, et al., 2026, Exploration of Multiple Mechanisms and Countermeasures for Immune Resistance in Biliary Tract Malignancies. Abdominal Surgery, 39(1): 1–8 + 23.